文献速递血脂与心血管预防心力衰竭与心肌病心律失常

癌症幸存者心血管风险预测模型的荟萃分析

Cardiovascular risk-prediction models in cancer survivors: a meta-analysis.
PubMed 文献 · Eur Heart J · 2026-01-01

约三分之一的模型-结局评估达到可接受至良好区分度(AUC≥0.70),模型性能因癌症类型而异,乳腺癌队列较一致,血液恶性肿瘤幸存者明显较差。

要点

  • 约三分之一模型-结局评估AUC≥0.70,通用人群模型对血管事件有4个、CTRCD/心衰有3个、心律失常有2个达可接受至良好区分度。
  • 癌症特异性评分如HFA-ICOS和Ezaz评分对特定结局特异性高,可支持rule-in决策,但敏感性较低限制其排除CTRCD/心衰风险。
  • 模型性能因癌症类型而异,乳腺癌队列区分度较一致,血液恶性肿瘤幸存者明显较差,提示跨癌种可移植性有限。

核心结论

  • 现有心血管风险预测工具在癌症幸存者中约三分之一评估达可接受至良好区分度,但跨癌种可移植性有限。
  • 需开发暴露感知、经外部验证且针对特定癌症人群定制的模型。

主要发现

  • 约三分之一模型-结局评估AUC≥0.70。
  • 通用人群模型中,4个风险评分对血管事件达可接受至良好区分度,3个对CTRCD/心衰可接受,2个对心律失常可接受。
  • 新西兰CVD评分是唯一复合结局模型AUC≥0.70。
  • 癌症特异性评分HFA-ICOS和Ezaz评分对特定结局特异性高但敏感性较低。
  • 亚组分析显示乳腺癌队列区分度较一致,血液恶性肿瘤幸存者性能明显较差。

关键数值与推荐

  • 可接受至良好区分度定义为AUC≥0.70。
  • 通用人群模型:4个对血管事件、3个对CTRCD/心衰、2个对心律失常达可接受至良好区分度。
  • 新西兰CVD评分为唯一复合结局模型AUC≥0.70。

临床怎么用

  • 临床选择模型时应考虑癌症类型,乳腺癌幸存者可用区分度较一致的模型,血液恶性肿瘤幸存者需谨慎。
  • 癌症特异性评分高特异性可支持rule-in决策,但低敏感性不宜用于排除CTRCD/心衰风险。

局限性

  • 模型性能因癌症类型而异,跨癌种可移植性有限。
  • 癌症特异性评分敏感性较低,限制排除风险的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This systematic review and meta-analysis included 34 studies encompassing 983 438 adult cancer survivors and evaluated the performance of both general-population and cancer-specific cardiovascular risk-prediction models across vascular events, cancer therapy-related cardiac dysfunction or heart failure, arrhythmias, and composite cardiovascular event outcomes. In total, 27 unique risk scores were assessed. Approximately one-third of model-outcome evaluations demonstrated acceptable-to-good discrimination, defined as an area under the curve of ≥0.70. Among general-population models, four risk scores demonstrated acceptable-to-good discrimination for vascular events, three models were acceptable for CTRCD/heart failure, and two models for arrhythmias. The New Zealand CVD score was the only composite outcome model with an AUC ≥0.70. Cancer-specific scores, such as HFA-ICOS and the Ezaz score, showed high specificity for selected outcomes and may support rule-in decisions, although their lower sensitivity limits use for ruling out risk of CTRCD/heart failure. In our subgroup analysis, model performance varied by cancer type, with more consistent discrimination in breast cancer cohorts and substantially poorer performance in survivors of haematologic malignancies, indicating limited transportability across cancer populations. In summary, these findings provide a comprehensive overview of available cardiovascular risk-prediction tools and may assist clinicians in selecting appropriate models for primary cardiovascular prevention in cancer survivors while highlighting the need for exposure-aware, externally validated models tailored to specific cancer populations.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Kazemian S, Vakilpour A, Scherrer-Crosbie M, et al. Cardiovascular risk-prediction models in cancer survivors: a meta-analysis. Eur Heart J. 2026. PMID: 42517578. doi:10.1093/eurheartj/ehag562

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。